International Journal of Endocrinology and Metabolism

Published by: Kowsar

Baseline IGFBP - 3 as the Key Element to Predict Growth Response to Growth Hormone and IGF - 1 Therapy in Subjects with Non - GH Deficient Short Stature and IGF - 1 Deficiency

Sheila Perez-Colon 1 , Oksana Lazareva 2 , Radhika Purushothaman 3 , Shahid Malik 4 , Svetlana Ten 5 and Amrit Bhangoo 6 , *
Authors Information
1 Division of Pediatric Endocrinology at SUNY Downstate Medical Center and Kings County Hospital, Brooklyn, NY, USA
2 Pediatric Specialists of Virginia Fairfax, VA, USA
3 Pediatric Endocrinology, Randall Children’s Hospital, Portland OR, USA
4 Department of Medicine, NYU Woodhull Medical and Mental Health Center Brooklyn, NY, USA
5 Ten’s Medical PC, Staten Island, NY, USA
6 Pediatric Endocrinology Children’s Hospital of Orange County, Orange CA, USA
Article information
  • International Journal of Endocrinology and Metabolism: July 2018, 16 (3); e58928
  • Published Online: May 21, 2018
  • Article Type: Research Article
  • Received: August 3, 2017
  • Revised: April 5, 2018
  • Accepted: April 8, 2018
  • DOI: 10.5812/ijem.58928

To Cite: Perez-Colon S, Lazareva O, Purushothaman R, Malik S, Ten S, et al. Baseline IGFBP - 3 as the Key Element to Predict Growth Response to Growth Hormone and IGF - 1 Therapy in Subjects with Non - GH Deficient Short Stature and IGF - 1 Deficiency, Int J Endocrinol Metab. 2018 ; 16(3):e58928. doi: 10.5812/ijem.58928.

Copyright © 2018, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG, et al. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab. 2007;92(7):2480-6. doi: 10.1210/jc.2007-0204. [PubMed: 17356043].
  • 2. Bakker B, Frane J, Anhalt H, Lippe B, Rosenfeld RG. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J Clin Endocrinol Metab. 2008;93(2):352-7. doi: 10.1210/jc.2007-1581. [PubMed: 18000092].
  • 3. Kelnar CJ, Albertsson-Wikland K, Hintz RL, Ranke MB, Rosenfeld RG. Should we treat children with idiopathic short stature? Horm Res. 1999;52(3):150-7. doi: 10.1159/000023452. [PubMed: 10725780].
  • 4. Goddard AD, Covello R, Luoh SM, Clackson T, Attie KM, Gesundheit N, et al. Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med. 1995;333(17):1093-8. doi: 10.1056/NEJM199510263331701. [PubMed: 7565946].
  • 5. Sanchez JE, Perera E, Baumbach L, Cleveland WW. Growth hormone receptor mutations in children with idiopathic short stature. J Clin Endocrinol Metab. 1998;83(11):4079-83. doi: 10.1210/jcem.83.11.5238. [PubMed: 9814495].
  • 6. Salerno M, Balestrieri B, Matrecano E, Officioso A, Rosenfeld RG, Di Maio S, et al. Abnormal GH receptor signaling in children with idiopathic short stature. J Clin Endocrinol Metab. 2001;86(8):3882-8. doi: 10.1210/jcem.86.8.7759. [PubMed: 11502828].
  • 7. Sjoberg M, Salazar T, Espinosa C, Dagnino A, Avila A, Eggers M, et al. Study of GH sensitivity in chilean patients with idiopathic short stature. J Clin Endocrinol Metab. 2001;86(9):4375-81. doi: 10.1210/jcem.86.9.7850. [PubMed: 11549678].
  • 8. Bonioli E, Taro M, Rosa CL, Citana A, Bertorelli R, Morcaldi G, et al. Heterozygous mutations of growth hormone receptor gene in children with idiopathic short stature. Growth Horm IGF Res. 2005;15(6):405-10. doi: 10.1016/j.ghir.2005.08.004. [PubMed: 16213173].
  • 9. David A, Hwa V, Metherell LA, Netchine I, Camacho-Hubner C, Clark AJ, et al. Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity. Endocr Rev. 2011;32(4):472-97. doi: 10.1210/er.2010-0023. [PubMed: 21525302].
  • 10. Burren CP, Woods KA, Rose SJ, Tauber M, Price DA, Heinrich U, et al. Clinical and endocrine characteristics in atypical and classical growth hormone insensitivity syndrome. Horm Res. 2001;55(3):125-30. doi: 10.1159/000049983. [PubMed: 11549873].
  • 11. Seino Y, Yamashita S, Morisaki Y, Tanaka H, Chihara K, Tanaka T. Japanese growth prediction model for prepubertal children with growth hormone deficiency. J Pediatr Endocrinol Metab. 2012;25(9-10):909-15. doi: 10.1515/jpem-2012-0189. [PubMed: 23426820].
  • 12. Hintz RL, Attie KM, Baptista J, Roche A. Effect of growth hormone treatment on adult height of children with idiopathic short stature. Genentech Collaborative Group. N Engl J Med. 1999;340(7):502-7. doi: 10.1056/NEJM199902183400702. [PubMed: 10021470].
  • 13. Ranke MB, Schweizer R, Elmlinger MW, Weber K, Binder G, Schwarze CP, et al. Relevance of IGF-I, IGFBP-3, and IGFBP-2 measurements during GH treatment of GH-deficient and non-GH-deficient children and adolescents. Horm Res. 2001;55(3):115-24. doi: 10.1159/000049982. [PubMed: 11549872].
  • 14. Clayton PE, Ayoola O, Whatmore AJ. Patient selection for IGF-I therapy. Horm Res. 2006;65 Suppl 1:28-34. doi: 10.1159/000090644. [PubMed: 16508331].
  • 15. Woods KA, Dastot F, Preece MA, Clark AJ, Postel-Vinay MC, Chatelain PG, et al. Phenotype: genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab. 1997;82(11):3529-35. doi: 10.1210/jcem.82.11.4389. [PubMed: 9360502].
  • 16. Rosenfeld RG. IGF-I therapy in growth disorders. Eur J Endocrinol. 2007;157 Suppl 1:S57-60. doi: 10.1530/EJE-07-0187. [PubMed: 17785699].
  • 17. Kayemba-Kay's S, Epstein S, Hindmarsh P, Burguet A, Ingrand P, Hankard R. Does plasma IGF-BP3 measurement contribute to the diagnosis of growth hormone deficiency in children? Ann Endocrinol (Paris). 2011;72(3):218-23. doi: 10.1016/j.ando.2011.01.002. [PubMed: 21641574].
  • 18. Blum WF, Hall K, Ranke MB, Wilton P. Growth hormone insensitivity syndromes: a preliminary report on changes in insulin-like growth factors and their binding proteins during treatment with recombinant insulin-like growth factor I. Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes. Acta Paediatr Suppl. 1993;82 Suppl 391:15-9. [PubMed: 7693071].
  • 19. Buckway CK, Guevara-Aguirre J, Pratt KL, Burren CP, Rosenfeld RG. The IGF-I generation test revisited: a marker of GH sensitivity. J Clin Endocrinol Metab. 2001;86(11):5176-83. doi: 10.1210/jcem.86.11.8019. [PubMed: 11701674].
  • 20. Midyett LK, Rogol AD, Van Meter QL, Frane J, Bright GM, M. S. Study Group . Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2010;95(2):611-9. doi: 10.1210/jc.2009-0570. [PubMed: 19880790].
  • 21. Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab. 2001;86(3):1274-80. doi: 10.1210/jcem.86.3.7280. [PubMed: 11238520].
  • 22. Clayton P, Chatelain P, Tato L, Yoo HW, Ambler GR, Belgorosky A, et al. A pharmacogenomic approach to the treatment of children with GH deficiency or Turner syndrome. Eur J Endocrinol. 2013;169(3):277-89. doi: 10.1530/EJE-13-0069. [PubMed: 23761422]. [PubMed Central: PMC3731924].
  • 23. Marzano F, Ventura A, Caratozzolo MF, Aiello I, Mastropasqua F, Brunetti G, et al. The p53 family member p73 modulates the proproliferative role of IGFBP3 in short children born small for gestational age. Mol Biol Cell. 2015;26(15):2733-41. doi: 10.1091/mbc.E15-02-0105. [PubMed: 26063735]. [PubMed Central: PMC4571334].
  • 24. Faienza MF, Marzano F, Ventura AM, Wasniewska M, Valenzise M, Valletti A, et al. Regulation of IGFBP3 gene expression in short children born small for gestational age. Growth Horm IGF Res. 2011;21(6):349-55. doi: 10.1016/j.ghir.2011.09.003. [PubMed: 22001433].
  • 25. Braz AF, Costalonga EF, Montenegro LR, Trarbach EB, Antonini SR, Malaquias AC, et al. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome. J Clin Endocrinol Metab. 2012;97(4):E671-7. doi: 10.1210/jc.2011-2521. [PubMed: 22278433].
  • 26. Braz AF, Costalonga EF, Trarbach EB, Scalco RC, Malaquias AC, Guerra-Junior G, et al. Genetic predictors of long-term response to growth hormone (GH) therapy in children with GH deficiency and Turner syndrome: the influence of a SOCS2 polymorphism. J Clin Endocrinol Metab. 2014;99(9):E1808-13. doi: 10.1210/jc.2014-1744. [PubMed: 24905066].
  • 27. Costalonga EF, Antonini SR, Guerra G Jr, Coletta RR, Franca MM, Braz AF, et al. Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and -202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency. Pharmacogenomics J. 2012;12(5):439-45. doi: 10.1038/tpj.2011.13. [PubMed: 21468024].
  • 28. Chan Y, Salem RM, Hsu YH, McMahon G, Pers TH, Vedantam S, et al. Genome-wide Analysis of Body Proportion Classifies Height-Associated Variants by Mechanism of Action and Implicates Genes Important for Skeletal Development. Am J Hum Genet. 2015;96(5):695-708. doi: 10.1016/j.ajhg.2015.02.018. [PubMed: 25865494]. [PubMed Central: PMC4570286].
  • 29. Cheng I, DeLellis Henderson K, Haiman CA, Kolonel LN, Henderson BE, Freedman ML, et al. Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Metab. 2007;92(9):3660-6. doi: 10.1210/jc.2007-0790. [PubMed: 17566087].
  • 30. Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009;30(5):417-37. doi: 10.1210/er.2008-0028. [PubMed: 19477944]. [PubMed Central: PMC2819737].
  • 31. Grimberg A, Coleman CM, Burns TF, Himelstein BP, Koch CJ, Cohen P, et al. p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J Clin Endocrinol Metab. 2005;90(6):3568-74. doi: 10.1210/jc.2004-1213. [PubMed: 15769996]. [PubMed Central: PMC4145590].
  • 32. Schwarz HP, Birkholz-Walerzak D, Szalecki M, Walczak M, Galesanu C, Metreveli D, et al. One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age. Biol Ther. 2014;4(1-2):1-13. doi: 10.1007/s13554-014-0014-4. [PubMed: 24676989]. [PubMed Central: PMC4254863].
  • 33. Baxter RC, Martin JL. Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma. J Clin Invest. 1986;78(6):1504-12. doi: 10.1172/JCI112742. [PubMed: 2431001]. [PubMed Central: PMC423906].
  • 34. Olivecrona H, Hilding A, Ekstrom C, Barle H, Nyberg B, Moller C, et al. Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: serum levels and hepatic messenger ribonucleic acid responses in humans. J Clin Endocrinol Metab. 1999;84(2):553-60. doi: 10.1210/jcem.84.2.5466. [PubMed: 10022415].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments